In This Section

Agenda

The SNMMI Therapeutics Conference has been developed to educate nuclear medicine physicians, technologists, hospital administrators, nurses, oncologists, and patients about the “how to's” of establishing a nuclear medicine therapy program in their institution. This meeting will reach an audience that does not normally attend SNMMI meetings and who may not have the knowledge or resources of setting up or providing theranostic agents for their patients. 

Friday, October 25 

  1. 3:00 PM – 3:05 PM: Welcome, Phillip Koo, MD 
  2. 3:05 PM – 3:20 PM: Introduction to Theranostics, Daniel Pryma, MD 
    1. NM physician as clinician  
    2. Setting up the care team  
  3. 3:20 PM – 4:20 PM: Operations, Jennifer Kwak, MD; Phillip Koo, MD; Phillip Kuo, MD, PhD 
    1. 3:20 PM – 3:35 PM: Creating physical space for patient facing nuclear medicine clinics, (TBA) 
    2. 3:35 PM – 3:55 PM: Operationalizing a Lutathera clinic, Jennifer Kwak, MD 
    3. 3:55 PM – 4:05 PM: Operationalizing your practice for radium 223, Phillip Koo, MD 
    4. 4:05 PM – 4:20 PM: Operationalizing your practice for PSMA based therapies, Phillip Kuo, MD, PhD 
  4. 4:20 PM – 5:10 PM: Radiation Safety and Medical Physics, Michael Sheetz, MS, CHP, DABMP 
    1. 4:20 PM – 4:50 PM: Primer for the Radiation Safety Officer 
    2. 4:50 PM – 5:05 PM: What the patient needs to know 
    3. 5:05 PM – 5:10 PM: Waste management 
  5. 5:10 PM – 5:50 PM: Establishing Your Practice in Systemic Radiation Therapy, Sandy McEwan
    1. Role of a technologist in theranostics practice

 

Saturday, October 26 

Incorporating new therapies into existing clinical practice 

  1. 9:00 AM – 10:00 AM: Endocrine, Douglas Van Nostrand, MD, FACP, FACNM; Daniel Pryma, MD 
    1. 9:00 AM – 9:30 AM: 131I Latest Updates, Douglas Van Nostrand, MD, FACP, FACNM 
    2. 9:30 AM – 10:00 AM: MIBG, Daniel Pryma, MD 
  2. 10:00 AM – 12:00 PM: GI Therapy, Christopher Lieu, MD; Jennifer Kwak, MD 
    1. 10:00 AM – 10:30 AM: Overview of the treatment landscape in neuroendocrine malignancies, Christopher Lieu, MD; Jennifer Kwak, MD 
    2. 10:30 AM – 11:00 AM: Optimizing the use of Lutathera in clinical practice and cases, Jennifer Kwak, MD 
    3. 11:00 AM – 11:30 AM: Co-managing the patient with metastatic neuroendocrine disease, Christopher Lieu, MD 
    4. 11:30 AM – 12:00 PM: Discussion 
  3. 12:00 PM – 1:00 PM: BREAK (Break or Sponsor Event) 
  4. 1:00 PM – 3:30 PM: Prostate Therapy, Tanya Dorff, MD; Phillip Koo, MD; Phillip Kuo, MD, PhD 
    1. 1:00 PM – 1:30 PM: Overview of the treatment landscape in castration resistant prostate cancer, Tanya Dorff, MD 
    2. 1:30 PM – 2:00 PM: The role of radium 223, Phillip Koo, MD 
    3. 2:00 PM – 2:30 PM: Current status of PSMA based therapies and where will we be in the near future, Phillip Kuo, MD, PhD 
    4. 2:30 PM – 3:00 PM: Co-managing the patient with metastatic castration resistant prostate cancer, Tanya Dorff, MD; Phillip Koo, MD; Phillip Kuo, MD, PhD 
    5. 3:00 PM – 3:30 PM: Discussion 

 

Sunday, October 27 (8 AM – 12 PM)

  1. 8:00 AM – 8:50 AM: Billing and Regulatory Issues, Denise Merlino, CNMT, CPC, MBA, FSNMMIT; Shaemus Gleason 
    1. 8:00 AM – 8:30 AM: Coding and reimbursement, Denise Merlino, CNMT, CPC, MBA, FSNMMIT 
    2. 8:30 AM – 8:50 AM: Licensing, Shaemus Gleason 
  2. 8:50 AM – 9:20 AM: Roadmap/Overview/Wrap up, Phillip Koo, MD; Daniel Pryma, MD  
  3. 9:20 AM – 9:50 AM: Q&A, FAQs 
  4. 9:50 AM – 10:00 AM: Closing remarks, Phillip Koo, MD; Daniel Pryma, MD